Denali Therapeutics Inc. (DNLI) 已重新获得其研究性疗法DNL593(又称PTV:PGRN)的完整全球权利,该疗法旨在治疗GRN基因突变相关的额颞叶痴呆(FTD-GRN)。此次权益回归标志着Denali将全面主导该候选药物的后续开发、潜在商业化及所有相关战略决策。
Denali Therapeutics Inc. (DNLI) 已重新获得其研究性疗法DNL593(又称PTV:PGRN)的完整全球权利,该疗法旨在治疗GRN基因突变相关的额颞叶痴呆(FTD-GRN)。此次权益回归标志着Denali将全面主导该候选药物的后续开发、潜在商业化及所有相关战略决策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.